Moderna says patent ruling not to affect COVID-19 vaccine development
1 min read . Updated: 25 Jul 2020, 10:11 AM ISTAn administrative court run by the US Patent and Trademark Office rejects Moderna's arguments to invalidate a US patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine
Moderna Inc said on Friday its formula used in developing a COVID-19 vaccine was not covered under patents owned by Arbutus Biopharma.
An administrative court run by the U.S. Patent and Trademark Office on Thursday rejected Moderna's arguments to invalidate a U.S. patent owned by Arbutus, sparking worries over its efforts to develop next-generation vaccines, including a coronavirus vaccine.
Moderna said the court's ruling relates to actions it took in response to "longstanding aggressive posture" taken by Arbutus against developers of nucleic acid-based therapeutics and began well before the development of mRNA-1273, its COVID-19 vaccine candidate.
Moderna shares were up slightly in extended trading, while Arbutus shares closed down 20% on Friday.
Click here to read the Mint ePaperMint is now on Telegram. Join Mint channel in your Telegram and stay updated with the latest business news.
